Please login to the form below
Bevespi
This page shows the latest Bevespi news and features for those working in and with pharma, biotech and healthcare.
AZ builds case for its COPD triple as it chases GSK’s Trelegy
In KRONOS, there was a 52% reduction in the rate of moderate or severe COPD exacerbations with Breztri compared with AZ’s two-drug Bevespi glycopyrronium/formoterol fumarate, and a 17%
Latest news
-
AZ prepares to file COPD triple, taking on rival GSK
The data reveals that the drug was better than two-drug combinations in preventing COPD exacerbations, reducing attacks by 52% compared to AZ’s LAMA/LABA combination Bevespi (glycopyrronium/formoterol fumarate). ... Trelegy. AZ’s competitive position
-
AZ rival to GSK’s COPD drug Anoro fails head-to-head test
AstraZeneca’s two-drug chronic obstructive pulmonary disease (COPD) therapy Bevespi did not match up to a rival combination from GlaxoSmithKline (GSK) in a phase III trial. ... The results of the AERISTO trial are a blow to AZ’s ambitions for Bevespi
-
2017 set to be a "defining year" for AZ
And two other new launches, Bevespi (glycopyrrolate and formoterol fumarate) for chronic obstructive pulmonary disease (COPD) and combination diabetes therapy Qtern (saxagliptin and dapagliflozin), will also help drive the recovery, said
-
Boehringer starts to feel impact of Spiriva generics
AZ) - Bevespi (glycopyrrolate and formoterol fumarate) -approved in April.
More from news
Approximately 3 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
AstraZeneca: building a new ‘open innovation’ pharma company
AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Presenting Outstanding Outcomes from HCP Education in Multiple Myeloma at IMS in Athens
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
No results were found
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
